Home » Stocks » Ocular Therapeutix

Ocular Therapeutix, Inc. (OCUL)

Stock Price: $8.39 USD 0.55 (7.02%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $8.44 +0.05 (0.60%) Aug 3, 6:18 PM

Stock Price Chart

Key Info

Market Cap 526.67M
Revenue (ttm) 6.34M
Net Income (ttm) -90.76M
Shares Out 62.77M
EPS (ttm) -1.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $8.39
Previous Close $7.84
Change ($) 0.55
Change (%) 7.02%
Day's Open 7.90
Day's Range 7.84 - 8.46
Day's Volume 551,987
52-Week Range 2.46 - 9.27

More Stats

Market Cap 526.67M
Enterprise Value 536.88M
Earnings Date (est) Aug 7, 2020
Ex-Dividend Date n/a
Shares Outstanding 62.77M
Float 46.66M
EPS (basic) -1.92
EPS (diluted) -1.90
FCF / Share -1.52
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.88M
Short Ratio 5.95
Short % of Float 10.75%
Beta 1.61
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 83.02
PB Ratio 22.80
Revenue 6.34M
Operating Income -82.76M
Net Income -90.76M
Free Cash Flow -78.81M
Net Cash -10.22M
Net Cash / Share -0.16
Gross Margin -617.73%
Operating Margin -1,304.51%
Profit Margin -1,430.60%
FCF Margin -1,242.24%
ROA -59.33%
ROE -1,211.02%
ROIC -119.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$12.60*
(50.18% upside)
Low
10.0
Current: $8.39
High
15.0
Target: 12.60
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue4.231.991.921.891.750.77-0.01
Revenue Growth112.41%3.48%1.91%7.83%126.68%---
Gross Profit1.901.531.471.441.430.68--
Operating Income-85.80-59.12-61.92-43.33-38.20-27.09-12.90-13.67
Net Income-86.37-59.98-63.39-44.70-39.75-28.65-13.32-14.09
Shares Outstanding45.2738.1228.8224.8223.2410.652.612.52
Earnings Per Share-1.91-1.57-2.20-1.80-1.71-2.69-5.11-5.60
Operating Cash Flow-77.58-49.23-50.47-34.00-33.74-20.50-12.65-12.59
Capital Expenditures-2.24-1.89-8.25-1.92-1.77-1.26-0.39-0.20
Free Cash Flow-79.82-51.12-58.72-35.92-35.51-21.76-13.03-12.79
Cash & Equivalents56.2060.6843.1569.8710575.0617.7324.08
Total Debt59.3424.7918.0215.6415.2714.872.464.07
Net Cash / Debt-3.1435.8925.1454.2390.0260.1915.2820.02
Assets78.7473.0455.4374.9411078.1919.1525.29
Liabilities82.3737.1729.2822.9320.7219.504.276.07
Book Value-3.6335.8826.1552.0189.5958.70-59.47-46.61
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ocular Therapeutix, Inc.
Country United States
Employees 161
CEO Antony Mattessich

Stock Information

Ticker Symbol OCUL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: OCUL
IPO Date July 25, 2014

Description

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert), which has completed two Phase III clinical trials for the treatment of post-surgical ocular pain and inflammation, and allergic conjunctivitis; and DEXTENZA, which is in Phase III clinical trials for the treatment of dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert), which is in Phase III clinical trials for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant, which is in Phase I clinical trials for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant, which is in Phase I clinical trials for the treatment of wet age-related macular degeneration(AMD). Its various preclinical programs include OTX- BPI for the treatment of acute ocular pain; OTX-BDI to treat post-operative Pain, and inflammation and bacterial infection; OTX-CSI to treat dry-eye disease; and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.